AP Biosciences Inc.

AP Biosciences Inc. is a biotechnology company focused on pioneering the development of bispecific antibody drugs and immunotherapy solutions. Established in 2013 and headquartered in Taipei, it operates as a clinical-stage biopharmaceutical innovator with an emphasis on addressing unmet medical needs, particularly within oncology and autoimmune disease fields. The company's portfolio includes advanced candidates such as IBI302, targeting neovascular age-related macular degeneration, and AP505 and AP203, which are being evaluated for solid tumors and various carcinomas in ongoing clinical trials. AP Biosciences is recognized for its proprietary T-cube bispecific antibody platform and OmniMab fully human antibody library, underlining its commitment to precision therapies that bridge the gap between traditional antibody drugs and next-generation biotherapeutics. The company holds a notable role in the regional biotech market, frequently collaborating with international pharmaceutical partners and licensing its innovations, thereby facilitating accelerated drug development and global market reach.